Immunocore Holdings PLC
NASDAQ:IMCR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.14
75.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Immunocore Holdings PLC
Immunocore Holdings PLC
Total Assets
Immunocore Holdings PLC
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Assets
£597m
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Assets
$360.2m
|
CAGR 3-Years
213%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Total Assets
£510.7m
|
CAGR 3-Years
69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Total Assets
$375.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Assets
$996.7m
|
CAGR 3-Years
52%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Assets
£1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Immunocore Holdings PLC
Glance View
Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.
See Also
What is Immunocore Holdings PLC's Total Assets?
Total Assets
597m
GBP
Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Total Assets amounts to 597m GBP.
What is Immunocore Holdings PLC's Total Assets growth rate?
Total Assets CAGR 5Y
25%
Over the last year, the Total Assets growth was 37%. The average annual Total Assets growth rates for Immunocore Holdings PLC have been 45% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
